Move to topTop

Following recent approval by the US Food and Drug Administration (FDA) of the TREO™ Abdominal Aortic Stent-Graft System for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic announced today the publication of the primary endpoint results from the investigational device exemption (IDE) pivotal study in the Journal of Vascular Surgery.

Over a three-year period, a multicentre, non-randomised, investigational device exemption (IDE) pivotal study assessed the safety and effectiveness of TREO. A total of 150 patients with infrarenal abdominal aortic or aorto-iliac aneurysms were treated in 29 centres across the United States. Follow-up continues but the primary safety and effectiveness endpoint analysis is now complete and demonstrated 100% technical success, only 0.7% incidence of major adverse events at 30 days, and 93.1% successful aneurysm treatment at one year.

In line with previous studies such as the global RATIONALE registry, a high percentage of patients had positive aortic remodeling with 54.3% who had aneurysm sac shrinkage > 5 mm at three years.

Principal investigator of the study and author, Matthew J. Eagleton, MD (Chief, Division of Vascular and Endovascular Surgery and Co-Director, Fireman Vascular Center, Massachusetts General Hospital, Boston, US) commented: "TREO is a new generation EVAR device designed to improve deployment and fixation, and increase the potential to treat more complex aortas with a wider range of sizing options and a number of engineering features to ensure durability for better longer-term outcomes. Research continues with ongoing follow-up of the IDE cohort for a maximum of 10 years."

One of the authors of the study, Michael C. Stoner, MD (Professor and Chief, Vascular Surgery, University of Rochester, New York, US) commented on the consistently good sac regression observed with TREO saying: "Worldwide experience with this device along with publications from our groups have already suggested that TREO is linked to positive remodeling. Certainly, data to three years in the IDE study are in line with those earlier findings and, as we gain more experience with TREO, it will be beneficial to develop an even better understanding of the physiological factors contributing to sac regression."

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.